The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –NEW YORK, March 18, ...

China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...

Cancer impacts millions globally, with lifestyle choices such as smoking, diet, physical activity, alcohol consumption, sun ...